NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild.
Patient undergoes an eye exam. National Eye Institute
Bethesda, Maryland–(ENEWSPF)–February 29, 2016. A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision. Gains after two years…
